(2S,3S,4S,5S)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol | 1105054-45-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2S,3S,4S,5S)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
• CAS: 1105054-45-2
• 化学式: C₆H₁₄N₂O₃
• 分子量: 162.189
• InChiKey: NJOZFAFEQVQFJI-BXKVDMCESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  98.7
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S,3S,4S,5S)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol 、 乙酸酐 反应 0.17h， 以92%的产率得到N-(((2S,3S,4S,5S)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl)methyl)acetamide
  参考文献：
  名称：

  A convenient approach toward the synthesis of enantiopure isomers of DMDP and ADMDP

  摘要：

  A practical method for the synthesis of five-membered iminocyclitols, pyrrolidine alkaloids bearing multiple hydroxyl substituents, has been developed. All of the eight key intermediates, enantiopure tri-O-benzyl cyclic nitrones, are prepared from four cheap, readily available D-aldopentoses. The nucleophilic addition of cyclic nitrones with vinyl magnesium chloride and TMSCN shows high 2,3-trans stereoselectivity. To construct the 2,3-cis configurations, inversion of the C-2 nitrile group is achieved via an elimination-reduction sequence. Using this approach, five isomers of DMDP and six isomers of ADMDP are prepared efficiently. In the biological evaluation, iminocyclitol 27 is a new and potent inhibitor against beta-hexosaminidase with an IC50 value of 0.2 mu M. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.10.096
• 作为产物：
  描述：

  (3S,4S,5S)-3,4-dibenzyloxy-5-benzyloxymethyl-1-pyrroline-N-oxide 在 二碳酸二叔丁酯 、 氢气 作用下， 以 甲醇 为溶剂， 反应 20.0h， 生成 (2S,3S,4S,5S)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
  参考文献：
  名称：

  Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency

  摘要：

  A unique molecular library consisting of all sixteen synthetic ADMDP (1-aminodeoxy-DMDP) stereo-isomers has been prepared and evaluated for inhibitory activity against alpha-Gal A, and ability to impart thermal stabilization of this enzyme. The results of this testing led us to develop a novel pharmacological chaperone for the treatment of Fabry disease. 3-Epimer ADMDP was found to be an effective pharmacological chaperone, able to rescue alpha-Gal A activity in the lymphoblast of the N215S Fabry patient derived cell line, without impairment of cellular 0-galactosidase activity. When 3-epimer ADMDP was administered with rh-alpha-Gal A (enzyme replacement therapy) for the treatment of Fabry patient-derived cell lines, improvements in the efficacy of rh-alpha-Gal A was observed, which suggests this small molecule can also provide clinical benefit of enzyme replacement therapy in Fabry disease. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.07.025

文献信息

• From Natural Product‐Inspired Pyrrolidine Scaffolds to the Development of New Human Golgi α‐Mannosidase II Inhibitors
  作者：Ting‐Jen R. Cheng、Ting‐Hao Chan、En‐Lun Tsou、Shang‐Yu Chang、Wen‐Yi Yun、Pei‐Jung Yang、Ying‐Ta Wu、Wei‐Chieh Cheng

  DOI：10.1002/asia.201300680

  日期：2013.11

  of sixteen natural product‐inspired polyhydroylated pyrrolidine‐based isomeric scaffolds is described. Each scaffold possesses four stereogenic centers and one exo‐aminomethyl moiety, which allows for rapid substituent diversity. To exemplify biological applications, these new privileged scaffolds were used to discover new human Golgi α‐mannosidase II inhibitors. The most potent inhibitor shows competitive

  一点启发：本文描述了系统地制备16种以自然产物为灵感的多氢基吡咯烷基异构支架的方法。每个支架都具有四个立体定位中心和一个外氨基氨基甲基部分，可实现快速的取代基多样性。为了举例说明生物学应用，这些新的特权支架被用于发现新的人类高尔基α-甘露糖苷酶II抑制剂。最有效的抑制剂表现出竞争行为，K i值为24 nM。
• [EN] METHODS OF TREATING POMPE DISEASE<br/>[FR] MÉTHODES DE TRAITEMENT DE LA MALADIE DE POMPE
  申请人：ACADEMIA SINICA

  公开号：WO2021067324A1

  公开（公告）日：2021-04-08

  Disclosed herein are novel uses of ADMDP stereoisomers or their derivatives for the manufacture of a medicament for treating Pompe disease. Accordingly, the present disclosure provides a method of treating Pompe disease in a subject. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), or a salt, an ester or a solvate thereof, wherein R1 and R2 are independently H or alkyl optionally substituted by -NH2 or -OH, so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the Pompe disease. According to certain embodiments of the present disclosure, the compound of formula (I) may serve a stabilizer of α-glucosidase via preventing its denaturalization of deactivation.

  本公开揭示了ADMDP立体异构体或其衍生物的新用途，用于制造治疗庞贝病的药物。因此，本公开提供了一种治疗庞贝病的方法。该方法包括向受试者施用化合物(I)的治疗有效量，或其盐、酯或溶剂，其中R1和R2独立地为H或烷基，可以选择地被-NH2或-OH取代，以改善、减轻、缓解和/或预防与庞贝病相关的症状。根据本公开的某些实施例，化合物(I)可以作为α-葡萄糖苷酶的稳定剂，通过防止其变性或失活。
• Treatment of Fabry disease
  申请人：Academia Sinica

  公开号：US10995067B2

  公开（公告）日：2021-05-04

  Disclosed herein are novel uses of a polyhydroxylated pyrrolidine for the manufacture of a medicament for treating Fabry disease (FD). Accordingly, the present disclosure provides a method of treating a subject having or suspected of having FD. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), a salt, an ester or a solvate thereof, wherein: R1 is H, or C1-3 amine optionally substituted with —COR2; R2 is alkyl or alkene optionally substituted with cycloalkyl or phenyl having at least one substituent selected from the group consisting of, halo, alkyl, haloalkyl, and alkoxyl; so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the FD. According to preferred embodiments of the present disclosure, the compound of formula (I) is a chaperon of a mutated human lysosomal α-galactosidase A (α-Gal A).

  本文公开了一种聚羟基吡咯烷的新用途，用于制造治疗法布里病（FD）的药物。因此，本公开提供了一种治疗法布里病或疑似法布里病受试者的方法。该方法包括以下步骤：向受试者施用治疗有效量的式(I)化合物、其盐、酯或溶液，其中：R1是H，或任选被-COR2取代的C1-3胺；R2是烷基或烯基，任选被环烷基或苯基取代，环烷基或苯基具有至少一个选自由卤代、烷基、卤代烷基和烷氧基组成的组的取代基；从而改善、减轻和/或预防与FD相关的症状。根据本公开的优选实施方案，式（I）化合物是突变的人溶酶体 α-半乳糖苷酶 A（α-Gal A）的合子。
• Harnessing polyhydroxylated pyrrolidines as a stabilizer of acid alpha-glucosidase (GAA) to enhance the efficacy of enzyme replacement therapy in Pompe disease
  作者：Huang-Yi Li、Ni-Chung Lee、Yu-Ting Chiu、Yu-Wen Chang、Chu-Chung Lin、Cheng-Li Chou、Yin-Hsiu Chien、Wuh-Liang Hwu、Wei-Chieh Cheng

  DOI：10.1016/j.bmc.2022.117129

  日期：2023.1
• TREATMENT OF FABRY DISEASE
  申请人：Academia Sinica

  公开号：US20190225579A1

  公开（公告）日：2019-07-25

  Disclosed herein are novel uses of a polyhydroxylated pyrrolidine for the manufacture of a medicament for treating Fabry disease (FD). Accordingly, the present disclosure provides a method of treating a subject having or suspected of having FD. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), a salt, an ester or a solvate thereof, wherein: R 1 is H, or C 1-3 amine optionally substituted with —COR 2 ; R 2 is alkyl or alkene optionally substituted with cycloalkyl or phenyl having at least one substituent selected from the group consisting of, halo, alkyl, haloalkyl, and alkoxyl; so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the FD. According to preferred embodiments of the present disclosure, the compound of formula (I) is a chaperon of a mutated human lysosomal α-galactosidase A (α-Gal A).